Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Price:
1 350.9
INR
0.71%
Market Cap:
1.1T
INR
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
DRREDDY Alert
Dr Reddy's Laboratories Ltd
1350.9
+9.55 (+0.71%)
| 52 Week Range |
1 092.5329
1 411.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Dr Reddy's Laboratories Ltd
Balance Sheet
Balance Sheet Decomposition
Dr Reddy's Laboratories Ltd
Dr Reddy's Laboratories Ltd
| Current Assets | 248.2B |
| Cash & Short-Term Investments | 66.5B |
| Receivables | 84.4B |
| Other Current Assets | 97.3B |
| Non-Current Assets | 219.1B |
| Long-Term Investments | 7.1B |
| PP&E | 85.8B |
| Intangibles | 105.3B |
| Other Non-Current Assets | 20.9B |
| Current Liabilities | 129.2B |
| Accounts Payable | 30.2B |
| Other Current Liabilities | 99B |
| Non-Current Liabilities | 30.6B |
| Long-Term Debt | 7.4B |
| Other Non-Current Liabilities | 23.2B |
Balance Sheet
Dr Reddy's Laboratories Ltd
Dr Reddy's Laboratories Ltd
Currency: INR
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
5 337
|
4 859
|
3 801
|
2 566
|
2 104
|
1 929
|
14 643
|
14 694
|
5 623
|
6 950
|
|
| Cash |
3 887
|
1 582
|
1 068
|
1 384
|
1 993
|
1 870
|
5 867
|
12 384
|
2 695
|
4 350
|
|
| Cash Equivalents |
1 450
|
3 277
|
2 733
|
1 182
|
111
|
59
|
8 776
|
2 310
|
2 928
|
2 600
|
|
| Short-Term Investments |
34 259
|
35 034
|
14 271
|
18 330
|
22 529
|
23 687
|
19 744
|
29 513
|
56 019
|
74 363
|
|
| Total Receivables |
51 239
|
51 551
|
49 197
|
54 061
|
51 454
|
60 875
|
61 337
|
78 083
|
87 993
|
98 831
|
|
| Accounts Receivables |
40 698
|
41 250
|
37 986
|
40 527
|
39 869
|
50 278
|
49 641
|
66 764
|
72 485
|
80 298
|
|
| Other Receivables |
10 541
|
10 301
|
11 211
|
13 534
|
11 585
|
10 597
|
11 696
|
11 319
|
15 508
|
18 533
|
|
| Inventory |
25 529
|
25 579
|
28 528
|
29 089
|
33 579
|
35 067
|
45 412
|
50 884
|
48 670
|
63 552
|
|
| Other Current Assets |
1 732
|
917
|
1 040
|
938
|
1 435
|
4 433
|
4 367
|
4 649
|
5 950
|
4 357
|
|
| Total Current Assets |
118 096
|
117 940
|
96 837
|
104 984
|
111 101
|
125 991
|
145 503
|
177 823
|
204 255
|
248 053
|
|
| PP&E Net |
46 945
|
52 756
|
56 376
|
57 411
|
53 852
|
52 143
|
56 861
|
61 665
|
66 294
|
75 997
|
|
| PP&E Gross |
0
|
52 756
|
56 376
|
57 411
|
53 852
|
52 143
|
56 861
|
61 665
|
66 294
|
75 997
|
|
| Accumulated Depreciation |
0
|
35 505
|
42 324
|
49 553
|
55 081
|
62 860
|
70 046
|
79 198
|
85 220
|
92 587
|
|
| Intangible Assets |
7 801
|
15 946
|
41 413
|
41 643
|
42 734
|
26 798
|
35 248
|
27 011
|
30 724
|
36 951
|
|
| Goodwill |
4 319
|
4 650
|
4 763
|
5 331
|
4 659
|
4 913
|
5 599
|
5 473
|
5 474
|
5 501
|
|
| Note Receivable |
1 395
|
1 556
|
1 433
|
5 648
|
4 267
|
6 887
|
3 769
|
3 847
|
2 891
|
4 671
|
|
| Long-Term Investments |
3 904
|
3 458
|
6 977
|
4 745
|
3 511
|
3 271
|
8 435
|
8 089
|
5 421
|
5 720
|
|
| Other Long-Term Assets |
8 190
|
7 535
|
10 366
|
5 681
|
4 532
|
12 250
|
10 753
|
13 561
|
7 792
|
11 745
|
|
| Other Assets |
4 319
|
4 650
|
4 763
|
5 331
|
4 659
|
4 913
|
5 599
|
5 473
|
5 474
|
5 501
|
|
| Total Assets |
190 650
N/A
|
203 841
+7%
|
218 165
+7%
|
225 443
+3%
|
224 656
0%
|
232 253
+3%
|
266 168
+15%
|
297 469
+12%
|
322 851
+9%
|
388 638
+20%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
8 493
|
9 068
|
10 569
|
13 345
|
13 671
|
15 248
|
18 109
|
22 662
|
22 684
|
26 144
|
|
| Accrued Liabilities |
12 436
|
16 350
|
15 392
|
17 153
|
18 371
|
21 439
|
21 399
|
24 036
|
28 019
|
29 711
|
|
| Short-Term Debt |
21 857
|
22 718
|
43 626
|
25 562
|
12 125
|
16 532
|
23 145
|
27 082
|
7 390
|
12 723
|
|
| Current Portion of Long-Term Debt |
6 962
|
110
|
110
|
63
|
4 256
|
4 266
|
864
|
1 017
|
4 804
|
1 307
|
|
| Other Current Liabilities |
13 986
|
15 225
|
14 502
|
12 815
|
10 550
|
14 656
|
17 521
|
22 861
|
22 824
|
25 995
|
|
| Total Current Liabilities |
63 734
|
63 471
|
84 199
|
68 938
|
58 973
|
72 141
|
81 038
|
97 658
|
85 721
|
95 880
|
|
| Long-Term Debt |
14 307
|
10 685
|
5 449
|
25 089
|
22 000
|
1 304
|
6 299
|
5 746
|
1 278
|
5 990
|
|
| Deferred Income Tax |
791
|
537
|
1 620
|
1 950
|
473
|
20
|
289
|
14
|
760
|
841
|
|
| Other Liabilities |
3 484
|
3 450
|
4 276
|
3 750
|
2 974
|
2 800
|
2 125
|
1 927
|
2 231
|
3 379
|
|
| Total Liabilities |
82 316
N/A
|
78 143
-5%
|
95 544
+22%
|
99 727
+4%
|
84 420
-15%
|
76 265
-10%
|
89 751
+18%
|
105 345
+17%
|
89 990
-15%
|
106 090
+18%
|
|
| Equity | |||||||||||
| Common Stock |
852
|
853
|
829
|
830
|
830
|
831
|
832
|
832
|
833
|
834
|
|
| Retained Earnings |
85 723
|
102 813
|
112 243
|
117 781
|
133 520
|
150 147
|
165 604
|
183 428
|
224 561
|
272 550
|
|
| Additional Paid In Capital |
19 591
|
20 021
|
4 779
|
5 211
|
5 631
|
5 916
|
6 308
|
6 701
|
7 109
|
8 186
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
535
|
1 006
|
1 967
|
1 601
|
1 269
|
991
|
|
| Other Equity |
2 168
|
2 011
|
4 770
|
1 894
|
790
|
100
|
5 640
|
2 764
|
1 627
|
1 969
|
|
| Total Equity |
108 334
N/A
|
125 698
+16%
|
122 621
-2%
|
125 716
+3%
|
140 236
+12%
|
155 988
+11%
|
176 417
+13%
|
192 124
+9%
|
232 861
+21%
|
282 548
+21%
|
|
| Total Liabilities & Equity |
190 650
N/A
|
203 841
+7%
|
218 165
+7%
|
225 443
+3%
|
224 656
0%
|
232 253
+3%
|
266 168
+15%
|
297 469
+12%
|
322 851
+9%
|
388 638
+20%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
170
|
171
|
166
|
166
|
166
|
166
|
166
|
830
|
831
|
833
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
